Achieve life sciences names dr. mark rubinstein interim chief medical officer

Seattle and vancouver, british columbia, sept. 11, 2025 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced mark rubinstein, m.d., will assume the role of interim chief medical officer (cmo). dr. rubinstein will succeed cindy jacobs, ph.d., m.d., who we anticipate will provide advisory services to support the company's ongoing efforts to advance cytisinicline as a potential treatment option for nicotine dependence.
ACHV Ratings Summary
ACHV Quant Ranking